title: Chemotherapy-induced peripheral neuropathy.
abstract: Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival of patients and the promise of a return to normal lives. This progress comes with a price, however, and the nervous system is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxic attack is directed against the peripheral nerve, targeting the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures, resulting in chemotherapy-induced peripheral neuropathy.
authors.affiliation: Section of Headache and Pain, Department of Neurology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
authors.forename: Bushra
authors.initials: B
authors.lastname: Malik
authors.forename: Mark
authors.initials: M
authors.lastname: Stillman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents
references.citation: Muscle Nerve. 2005 Jul;32(1):51-60
references.pmid: 15880395
references.citation: Neurology. 1995 Oct;45(10):1848-55
references.pmid: 7477980
references.citation: Arch Neurol. 2003 Nov;60(11):1524-34
references.pmid: 14623723
references.citation: BMC Cancer. 2006 Jan 07;6:5
references.pmid: 16398939
references.citation: Neurol Clin. 2003 Feb;21(1):279-318, x
references.pmid: 12690653
references.citation: J Neurol. 1994 Jun;241(7):432-5
references.pmid: 7931444
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4843-50
references.pmid: 16000582
references.citation: Brain. 2007 Apr;130(Pt 4):1076-88
references.pmid: 17301082
references.citation: Rev Neurol (Paris). 1985;141(10):614-26
references.pmid: 3003868
references.citation: Eur J Cancer. 2005 Aug;41(12):1746-50
references.pmid: 16039110
references.citation: Cleve Clin J Med. 2006 Aug;73(8):726-8, 729-30, 733-6 passim
references.pmid: 16913197
references.citation: Neurology. 1999 Nov 10;53(8):1634-40
references.pmid: 10563605
references.citation: Neurology. 1989 Mar;39(3):368-73
references.pmid: 2564647
references.citation: Curr Pain Headache Rep. 2006 Aug;10(4):279-87
references.pmid: 16834943
references.citation: Ann Oncol. 2000 May;11(5):509-13
references.pmid: 10907941
references.citation: Neurosci Lett. 2006 Apr 24;397(3):219-23
references.pmid: 16406309
references.citation: Support Care Cancer. 2005 Aug;13(8):647-51
references.pmid: 15711945
references.citation: J Neurol. 2002 Jan;249(1):9-17
references.pmid: 11954874
references.citation: Neurology. 2002 Dec 24;59(12):1872-5
references.pmid: 12499476
references.citation: Ann Oncol. 1998 Jul;9(7):739-44
references.pmid: 9739440
references.citation: Muscle Nerve. 2004 Mar;29(3):387-92
references.pmid: 14981738
references.citation: Lancet. 2003 Jun 21;361(9375):2099-106
references.pmid: 12826431
references.citation: Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4055-61
references.pmid: 15217938
references.citation: Minerva Anestesiol. 2006 Mar;72(3):151-69
references.pmid: 16493391
references.citation: Pain. 2004 May;109(1-2):132-42
references.pmid: 15082135
references.citation: Brain. 1996 Dec;119 ( Pt 6):2039-52
references.pmid: 9010008
references.citation: J Clin Oncol. 2002 Aug 15;20(16):3478-83
references.pmid: 12177109
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1685-6
references.pmid: 15755987
references.citation: Clin Cancer Res. 2006 Apr 15;12(8):2607-12
references.pmid: 16638873
references.citation: Neurology. 2003 Jan 28;60(2):337-40
references.pmid: 12552058
references.citation: J Peripher Nerv Syst. 2006 Jun;11(2):135-41
references.pmid: 16787511
references.citation: Anticancer Drugs. 2005 Jun;16(5):587-91
references.pmid: 15846125
references.citation: Neurology. 2005 Jan 11;64(1):26-31
references.pmid: 15642899
references.citation: Curr Oncol Rep. 2005 May;7(3):159-60
references.pmid: 15847705
references.citation: Neurology. 1996 Jan;46(1):108-11
references.pmid: 8559355
references.citation: Cancer Invest. 2004;22(3):471-3
references.pmid: 15493367
references.citation: Semin Neurol. 1987 Mar;7(1):58-66
references.pmid: 3332448
references.citation: Semin Neurol. 2005 Jun;25(2):204-16
references.pmid: 15937736
references.citation: Clin Cancer Res. 2004 Jan 15;10(2):461-7
references.pmid: 14760066
references.citation: J Neurooncol. 1997 Oct;35(1):47-53
references.pmid: 9266440
references.citation: Cancer. 1996 Apr 1;77(7):1356-62
references.pmid: 8608515
references.citation: Clin Oncol (R Coll Radiol). 2005 Jun;17(4):271-6
references.pmid: 15997923
references.citation: Neurology. 2003 Nov 11;61(9):1297-300
references.pmid: 14610145
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1691-3
references.pmid: 15755989
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1890-8
references.pmid: 15756015
references.citation: Br J Cancer. 1997;75(3):417-22
references.pmid: 9020489
references.citation: J Clin Oncol. 2003 Mar 1;21(5):927-31
references.pmid: 12610195